A phase II trial of erlotinib and bevacizumab for patients with metastatic melanoma.

Sorry, there's nothing here.
020406020162017
Citations per Year

Citation Velocity: 10

Averaging 10 citations per year over the last 2 years.

Learn more about how we calculate this metric in our FAQ.

Cite this paper

@article{Mudigonda2016API, title={A phase II trial of erlotinib and bevacizumab for patients with metastatic melanoma.}, author={Tejaswi V Mudigonda and Kenneth Wyman and David Robert Spigel and Kimberly Brown Dahlman and Frank Anthony Greco and Igor J. Puzanov and Mark C. Kelley and John Hainsworth and Jeffrey A. Sosman and Douglas B. Johnson}, journal={Pigment cell & melanoma research}, year={2016}, volume={29 1}, pages={101-3} }